. . . . . . . "[By genetic modification of T cells with an NKG2D-based chimeric Ag receptor, referred to as chNKG2D in which the NKG2D receptor is fused to the signaling domain of CD3?-chain, T cells were capable of targeting tumor vasculature leading to reduced tumor angiogenesis and tumor growth.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2017-02-19"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2017-10-17T13:19:29+02:00"^^ . . . . . . . . . . . "v5.0.0.0" . "v5.0.0" .